Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Carole Nuechterlein
AddedMar 31, 2024
UpdatedMay 31, 2026
Carole Nuechterlein

Carole Nuechterlein

Board Member, Lysosomal Therapeutics

Crunchbase

Carole Nuechterlein's Career

Lysosomal Therapeutics
Lysosomal Therapeutics

Cambridge, MA, US

Board Member· Board
CiVi Biopharma
CiVi Biopharma

Chevy Chase, MD, US

Board Member· Board
Arch Oncology
Arch Oncology

St. Louis, MO, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Carole Nuechterlein's Career

Lysosomal Therapeutics
Lysosomal Therapeutics
Series A$24.8M52011Cambridge, MA, US
Board Member· Board

Leadership at Lysosomal Therapeutics

Clay ThorpClay ThorpBoard Member
Joseph MazzulliJoseph MazzulliCo-Founder
Kees BeenKees BeenCo-Founder
Bruce BoothBruce BoothBoard Member
Steve HallSteve HallBoard Member
Edmund SybertzEdmund SybertzCo-Founder
CiVi Biopharma
CiVi Biopharma
Public$89M142016Chevy Chase, MD, US
Board Member· Board

Leadership at CiVi Biopharma

Shal JacobovitzShal JacobovitzCEO
Henrik ØrumHenrik ØrumFounder
Aaron I DavisAaron I DavisBoard Member

Similar to CiVi Biopharma

CargeneCargeneCambridge, MA, USDrug Development, Therapeuticsest. 2020CargeneCambridge, MA, US · est. 2020

Cargene: A bio-pharmaceutical firm innovating oligonucleotide therapies for cardiovascular and lung diseases.

Seed · $19.2M26
Rivus PharmaceuticalsRivus PharmaceuticalsCharlottesville, VA, USPharmaceuticals, Therapeuticsest. 2019Rivus PharmaceuticalsCharlottesville, VA, US · est. 2019

Rivus Pharmaceuticals: Innovating cardio-metabolic health through small molecule therapeutics.

Series B · $167M11
Cardurion PharmaceuticalsCardurion PharmaceuticalsBurlington, MA, USTherapeuticsest. 2017Cardurion PharmaceuticalsBurlington, MA, US · est. 2017

Boston-based biotech firm specializing in next-gen therapeutics for heart diseases.

Series B · $343.1M42
BioCardiaBioCardiaSan Carlos, CA, USMedical Devices, Therapeuticsest. 1999BioCardiaSan Carlos, CA, US · est. 1999

BioCardia, a San Carlos-based medical firm, develops innovative regenerative therapies for critical cardiovascular diseases.

Public · $41.3M28
Arch Oncology
Arch Oncology
Series C$250.4M752006St. Louis, MO, US
Board Member· Board

Leadership at Arch Oncology

John McKearnJohn McKearnBoard Member
Julie HambletonJulie HambletonBoard Member
Robert KarrRobert KarrCEO
Eric PhamEric PhamBoard Member
Jill CarrollJill CarrollBoard Member
Peter MoldtPeter MoldtBoard Member

Similar to Arch Oncology

Immune-Onc TherapeuticsImmune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35
OncoResponseOncoResponseSeattle, WA, USBiomedical Servicesest. 2016OncoResponseSeattle, WA, US · est. 2016

OncoResponse Inc: A US-based biomedical services provider specializing in cancer care research and development.

Series B · $130.1M20
argenxargenxBoston, MA, USAntibody Therapiesest. 2008argenxBoston, MA, US · est. 2008

Argenx: Innovating antibody-based therapies for cancer and autoimmune diseases.

Public · $3.4B1.2k
Crossbow TherapeuticsCrossbow TherapeuticsCambridge, MA, USCancer Therapiesest. 2021Crossbow TherapeuticsCambridge, MA, US · est. 2021

Crossbow Therapeutics: A seed-stage startup innovating in antibody engineering for cancer targets.

Series B · $157M11

Carole Nuechterlein's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Carole Nuechterlein

Karen GrantKaren GrantCo-Founder · Angel One NetworkCarter GriffinCarter GriffinBoard Member · LiongardSalil PunalekarSalil PunalekarBoard Member · ScienapticTaylor WoodTaylor WoodCo-Founder · HomemationBill DonovanBill DonovanFounder · Wright Avenue PartnersRJ JonesRJ JonesCo-Founder · Advocado